Previously, the treatment algorithm for glaucoma relied on medical therapy at one end of the spectrum through to invasive procedures such as trabeculectomy at the other. Now, through close collaboration with teaching institutions, researchers and ophthalmic physicians, Nova Eye Medical is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
On 30 June 2020, the Company completed the divestment of the Ellex Lasers & Ultrasound business to Lumibird Group SA. As a result, Nova Eye Medical has a unique opportunity to leverage its platform technologies to build a comprehensive portfolio of novel glaucoma treatment technologies and devices. It also has an opportunity to advance the commercialization of the 2RT™ project.
5 Mar, 2021
2 Mar, 2021
25 Feb, 2021
Send an enquiry